EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer

Yuetong Zhang, Jiaying Chen, Yong She, Zhaoyuan Fang, Yaxin Zhang, Danyun Ruan, Wenjun Guo, Jianping Liao, Weiping Zhou, Jianpei Lao, Weicheng Fang, Xingyan Pan und 16 weitere

Cancer Cell · 2026-01 · 44 (1) · 77-93.e8

DOI: 10.1016/j.ccell.2025.10.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2026-01. Verfasst von Yuetong Zhang und 27 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Drug Resistance, Neoplasm, Proto-Oncogene Proteins p21(ras), Paneth Cells. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Norris Cotton Cancer Center, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While dual KRAS and epidermal growth factor receptor (EGFR) inhibition shows promise in treating KRAS-mutant colorectal cancer (CRC), resistance remains a major challenge. Using genetically engineered mouse models, patient-derived organoids and xenografts, as well as clinical specimens, we discover that colorectal tumors surviving combined KRAS and EGFR inhibition acquire a Paneth-like cell state-a secretory lineage typically confined to the intestinal crypt. Lineage tracing reveals that CRC cells evade dual therapy by transitioning into a Paneth-like state. Through integrated transcriptomic analysis and CRISPR genetic screening, we identify SMAD1 as a key regulator of this lineage plasticity, promoting resistance by directly activating FGFR3. Genetic or pharmacological inhibition of FGFR3 prevents the Paneth-like transition, restores drug sensitivity, and synergizes with KRAS-EGFR inhibition across multiple preclinical models. These findings reveal that the SMAD1-FGFR3 axis triggers Paneth-like plasticity to drive KRAS-EGFR dual therapy resistance in CRC and highlight FGFR3 blockade as a promising strategy to overcome plasticity-driven drug tolerance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsDrug Resistance, NeoplasmProto-Oncogene Proteins p21(ras)Paneth CellsAnimalsHumansErbB ReceptorsMiceReceptor, Fibroblast Growth Factor, Type 3Smad1 ProteinXenograft Model Antitumor AssaysCell Line, TumorProtein Kinase InhibitorsMutation

Stichwörter der Autor:innen

KRAS mutant colorectal cancerPaneth-like cell statedrug resistancedual KRAS and EGFR-targeted therapylineage plasticitytrans-differentiation

Substanzen

Proto-Oncogene Proteins p21(ras)ErbB ReceptorsEGFR protein, humanKRAS protein, humanReceptor, Fibroblast Growth Factor, Type 3FGFR3 protein, humanSmad1 ProteinProtein Kinase Inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, P.R.…
  • Bioinformatics Platform, Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, P.R. C…
  • Department of Colorectal Surgery and Oncology of the Second Affiliated Hospital, and Centre of Biomedical Systems and Informatics of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang Un…
  • Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou 510060, P.R. China; Department of Clinical Research, Sun Yat-sen University Cancer Center, S…
  • State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.

Förderung

  • NCI NIH HHS
  • Norris Cotton Cancer Center
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangzhou Municipal Science and Technology Project
  • National Natural Science Foundation of China
  • Sun Yat-sen University Cancer Center
  • Natural Science Foundation of Zhejiang Province
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Zhang, Y., Chen, J., She, Y., Fang, Z., Zhang, Y., Ruan, D., Guo, W., Liao, J., Zhou, W., Lao, J., Fang, W., Pan, X., Kang, W., Wang, Z., Wu, Y., Deng, R., Tian, L., Wang, L., Huang, H., …, & Gao, Y. (2026). Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer Cell, 44(1), 77-93.e8. https://doi.org/10.1016/j.ccell.2025.10.010

Vancouver

Zhang Y, Chen J, She Y, Fang Z, Zhang Y, Ruan D, et al. Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer Cell. 2026;44(1):77-93.e8. doi:10.1016/j.ccell.2025.10.010

BibTeX
@article{Zhang2026,
  author = {Zhang, Yuetong and Chen, Jiaying and She, Yong and Fang, Zhaoyuan and Zhang, Yaxin and Ruan, Danyun and Guo, Wenjun and Liao, Jianping and Zhou, Weiping and Lao, Jianpei and Fang, Weicheng and Pan, Xingyan and Kang, Wenfei and Wang, Zifeng and Wu, Yuanzhong and Deng, Rong and Tian, Lin and Wang, Liqin and Huang, Huilin and Zheng, Jian and Yan, Yan and Lu, Hezhe and Wang, Ruiping and Yaeger, Rona and Zhao, Qi and Liao, Wenting and Wang, Feng and Gao, Yijun},
  title = {Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer},
  journal = {Cancer Cell},
  year = {2026},
  volume = {44},
  number = {1},
  pages = {77--93.e8},
  doi = {10.1016/j.ccell.2025.10.010}
}
Kostenlos starten →